top of page

Emily Dworkin

PharmD, BCOP

Rotations

Outpatient Adult Leukemia, AYA cancer clinic

Education

PharmD: University of Iowa

Residency Training

PGY1: University of Wisconsin Health
PGY2 Oncology/Hematology: University of Wisconsin Health

Emily Dworkin

Practice Interests

Acute Leukemia, Adolescent and Young Adult (AYA) Cancers, Quality Improvement and Pharmacy Practice Advancement

Professional Affiliation

  • Hematology/Oncology Pharmacy Association (HOPA)

  • American Society of Health-System Pharmacists (ASHP)

Recent Publications

  • Bauer J, Craven A, Dworkin E, Drazer M. Implications of off-label prescribing of novel therapies in acute myeloid leukemia. Abstract. The Hematology/Oncology Pharmacy Association Annual Conference, Phoenix, AZ. March 2023.

  • Roloff GW, Wen F, Ramsland A… Dworkin E, et al. Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors [published online ahead of print, 2023 Jan 19]. Haematologica

  • Dworkin E, Signorelli J. A possible chemotherapy-free era for acute lymphoblastic leukemia? Oncolytics Today. Fall 2022. 38-45.

  • Cahill K, Alban J, Mortel M, Dworkin E, Kosuri S, Duvall A, Liu H, Bishop M, Larson R, Stock W. Low incidence of veno-occlusive disease in patients with B-cell acute lymphoblastic leukemia treated with inotuzumab followed by allogeneic stem cell transplant. The American Society of Clinical Oncology Annual Meeting, June 2021. J Clin Onc 39, 2021 (supp 15; abstract e19024).

  • Schmiegelow K, Rank CU, Stock W, Dworkin E, van der Sluis I. SOHO State of the art updates and next questions: management of asparaginase toxicity in adolescents and young adults with acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2021;21(11):725-733.

  • Patel AA, Heng J, Dworkin E, Monick S, Derman B, et al. Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. eJHaem. Published online June 2021.

  • Schulz LT, Dworkin E, Dela-Pena J, Rose WE. Multiple-dose oritavancin evaluation in a retrospective cohort of patients with complicated infections. Pharmacotherapy. 2018;38(1):152-159.

  • Dworkin E, Hager D. Taking the fear out of feedback: models for success. J Pharm Soc Wis.2016;19(2):22-25.

Academic and/or National Presentations

  • Optimal intensive induction for older adults with newly diagnosed acute myeloid leukemia. Presented at the Hematology/Oncology Pharmacy Association Annual Conference. Boston, MA. April 2022

  • Checkpoint inhibitors in hematologic malignancies. Recorded Lecture for The Hematology/Oncology Pharmacy Association 2021 BCOP Oncology Pharmacy Updates

  • Advances in targeted therapy for AML: Practical management of BCL-2 inhibitors. Abbvie Sponsored Symposium. Presented at The Hematology/Oncology Pharmacy Association Annual Conference. [Virtual] April 2021

Current Research

  • Off label prescribing of novel agents in acute myeloid leukemia, with Jordan Baur, PharmD

  • The impact of a pharmacist driven protocol for management of 6MP and oral MTX during AML maintenance therapy with Kaitlin Kelly, PharmD, BCOP

bottom of page